Dear Medical Care Group Business Administrator:
On April 13, 2022, we mailed a letter to one or more of your primary care physicians who have BCN AdvantageSM patients who are eligible for a new pilot program that uses pharmacogenomic (PGx) testing. Attached is a generic copy of the letter and the fact sheet that went to physicians, along with a copy of the letter mailed to members selected for the pilot program.
There will be a webinar on May 3 at noon Eastern Time reviewing the PGx program. We encourage you to register for this webinar and encourage your physicians to do so as well. You can also view other PGx videos at the registration link.
You may have also received two previous emails about this pilot program if you had physicians involved in these earlier mailings:
- Email of March 22, 2022: Letter to physicians with BCN Advantage patients eligible for the first round of this pilot program.
- Email of March 29, 2022: Letter to physicians with Blue Care Network commercial patients eligible for a similar program with a different vendor.
If you would like a list of your affected physicians and their members for any of these mailings, please reach out to your provider consultant.